Cargando…
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept can be used both as monotherapy and in combination with methotrexate (MTX), but direct comparisons of these two options have not yet been reported. In order to compare the results seen in actual practice between these two options, clinical data on 97 patients followed in the Stockholm TNF...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC333416/ https://www.ncbi.nlm.nih.gov/pubmed/14680509 http://dx.doi.org/10.1186/ar1005 |
_version_ | 1782121209150832640 |
---|---|
author | van Vollenhoven, Ronald F Ernestam, Sofia Harju, Anders Bratt, Johan Klareskog, Lars |
author_facet | van Vollenhoven, Ronald F Ernestam, Sofia Harju, Anders Bratt, Johan Klareskog, Lars |
author_sort | van Vollenhoven, Ronald F |
collection | PubMed |
description | Etanercept can be used both as monotherapy and in combination with methotrexate (MTX), but direct comparisons of these two options have not yet been reported. In order to compare the results seen in actual practice between these two options, clinical data on 97 patients followed in the Stockholm TNFα Follow-Up Registry were analysed. In 57 of these patients etanercept was added to previously started MTX while the others were treated with etanercept alone. The two groups had similar levels of disease activity at baseline. After 3 months, a significantly lower mean disease activity score (28-joint count-based disease activity score) was attained by the patients on etanercept plus MTX. In this group, the number of patients achieving European League Against Rheumatism-defined remission was also significantly greater. Other disease outcomes showed non-significant trends in the same direction. These data suggest that the combination of etanercept plus MTX is clinically more efficacious than etanercept alone. |
format | Text |
id | pubmed-333416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-3334162004-02-07 Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious van Vollenhoven, Ronald F Ernestam, Sofia Harju, Anders Bratt, Johan Klareskog, Lars Arthritis Res Ther Research Article Etanercept can be used both as monotherapy and in combination with methotrexate (MTX), but direct comparisons of these two options have not yet been reported. In order to compare the results seen in actual practice between these two options, clinical data on 97 patients followed in the Stockholm TNFα Follow-Up Registry were analysed. In 57 of these patients etanercept was added to previously started MTX while the others were treated with etanercept alone. The two groups had similar levels of disease activity at baseline. After 3 months, a significantly lower mean disease activity score (28-joint count-based disease activity score) was attained by the patients on etanercept plus MTX. In this group, the number of patients achieving European League Against Rheumatism-defined remission was also significantly greater. Other disease outcomes showed non-significant trends in the same direction. These data suggest that the combination of etanercept plus MTX is clinically more efficacious than etanercept alone. BioMed Central 2003 2003-10-01 /pmc/articles/PMC333416/ /pubmed/14680509 http://dx.doi.org/10.1186/ar1005 Text en Copyright © 2003 van Vollenhoven et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article van Vollenhoven, Ronald F Ernestam, Sofia Harju, Anders Bratt, Johan Klareskog, Lars Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
title | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
title_full | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
title_fullStr | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
title_full_unstemmed | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
title_short | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
title_sort | etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC333416/ https://www.ncbi.nlm.nih.gov/pubmed/14680509 http://dx.doi.org/10.1186/ar1005 |
work_keys_str_mv | AT vanvollenhovenronaldf etanerceptversusetanerceptplusmethotrexatearegistrybasedstudysuggestingthatthecombinationisclinicallymoreefficacious AT ernestamsofia etanerceptversusetanerceptplusmethotrexatearegistrybasedstudysuggestingthatthecombinationisclinicallymoreefficacious AT harjuanders etanerceptversusetanerceptplusmethotrexatearegistrybasedstudysuggestingthatthecombinationisclinicallymoreefficacious AT brattjohan etanerceptversusetanerceptplusmethotrexatearegistrybasedstudysuggestingthatthecombinationisclinicallymoreefficacious AT klareskoglars etanerceptversusetanerceptplusmethotrexatearegistrybasedstudysuggestingthatthecombinationisclinicallymoreefficacious |